Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CASP2 | P42575 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094912 | 0.97 | CYP1A2 (0.40) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL1230682 | 0.93 | CYP1A2 (0.42) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL5098312 | 0.93 | CYP1A2 (0.42) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL8764297 | 0.93 | CYP1A2 (0.42) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL5098259 | 0.93 | CYP1A2 (0.42) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL1066055 | 0.93 | — | — | |
| SCHEMBL1230675 | 0.87 | CYP1A2 (0.38) | CYP1A2CA12CA2CA4CA6 | |
| SCHEMBL4934708 | 0.86 | — | — | |
| SCHEMBL2488180 | 0.84 | — | — | |
| SCHEMBL25317055 | 0.82 | CA12 (0.61) | CYP1A2CA12CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084596-B2 | Regulated apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110003385-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-01-06 | — | — | US | disclosed |
| US-20100323420-A1 | REGULATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-12-23 | — | — | US | disclosed |
| EP-0804561-B1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | UNIV LELAND STANFORD JUNIOR (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090060888-A1 | Regulated transcription of targeted genes and other biological events | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | disclosed |
| EP-1978095-A1 | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20060078969-A1 | Regulated transcription of targeted genes and other biological events | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-13 | — | — | US | disclosed |
| US-20060035325-A1 | Regulated apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-02-16 | — | — | US | disclosed |
| US-6972193-B1 | Regulated transcription of targeted genes and other biological events | BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-12-06 | — | — | US | disclosed |
| US-6891021-B2 | Regulated apoptosis | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-05-10 | — | — | US | disclosed |
| US-5869337-A | OLIGOMERIZES TWO OR MORE CHIMERIC PROTEIN MOLECULES TO FORM A LIGAND CROSS-LINKED PROTEIN COMPLEX | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-02-09 | — | — | US | disclosed |
| US-5834266-A | A GENETIC CONSTRUCT ENCODING A CHIMERIC PROTEIN HAVING AN ACTIVATABLE APOPTOSIS-DOMAIN TO COMPLEX WITH A NONPROTEIN, MEMBRANE-PERMEABLE LIGAND WHICH THEN BINDS TO ANOTHER PROTEIN THEREBY ACTIVATING THE APOPTOSIS-INDUCING DOMAIN | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1998-11-10 | — | — | US | disclosed |
| US-5830462-A | DIMERIZATION, OLIGOMERIZATION OF PROTEINS; ACTIVATION OF CELLMEMBRANE RECEPTORS | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0776359-A4 | REGULATED APOPTOSIS | UNIV LELAND STANFORD JUNIOR (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0804561-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0776335-A1 | REGULATABLE ELIMINATION OF GENE EXPRESSION, GENE PRODUCT FUNCTION AND ENGINEERED HOST CELLS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776359-A1 | REGULATED APOPTOSIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006111-A1 | REGULATABLE ELIMINATION OF GENE EXPRESSION, GENE PRODUCT FUNCTION AND ENGINEERED HOST CELLS | ARIAD GENE THERAPEUTICS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995002684-A1 | REGULATED APOPTOSIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994018317-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060888-A1 | Regulated transcription of targeted genes and other biological events | NFATC1, CD4, ACIN1 | CYP1A2 4854/4885CA12 3972/4885CA2 3546/4885 |
| US-20060035325-A1 | Regulated apoptosis | BAX, CCAR2, DDIT3 | CYP1A2 4822/4885CA12 4326/4885CA2 4239/4885 |
| US-20060078969-A1 | Regulated transcription of targeted genes and other biological events | DGKZ, BID, TARBP1 | CYP1A2 4754/4885CA12 4429/4885CA2 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.